Clinical Trials Logo

Dyspepsia clinical trials

View clinical trials related to Dyspepsia.

Filter by:

NCT ID: NCT00333372 Completed - Clinical trials for Functional Dyspepsia

To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia

Start date: April 2006
Phase: Phase 2
Study type: Interventional

To Evaluate the efficacy of Z-338 in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms in order to further determine the optimal dosage and efficacy parameters for PhaseIII clinical trials.

NCT ID: NCT00328679 Completed - Dyspepsia Clinical Trials

Evaluation of Food Hypersensitivity in Children/Adolescents With Functional Dyspepsia

Start date: June 2006
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine if standard and investigational tests used to help diagnose and treat food allergies can provide information that will be useful in determining the cause of dyspepsia and helpful in designing a treatment plan. The study will also determine if there is a connection between positive allergy tests and inflammation in the upper abdomen.

NCT ID: NCT00323817 Completed - Clinical trials for Functional Dyspepsia

To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

Start date: April 2006
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia

NCT ID: NCT00303264 Completed - Dyspepsia Clinical Trials

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

Start date: May 2006
Phase: Phase 2
Study type: Interventional

"Functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." The symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting. These symptoms may present with or without the co-existence of symptoms of heartburn or gastroesophageal reflux disease (GERD). Functional dyspepsia is a diagnosis of exclusion in which other disease states, such as ulcer, cancer, etc. are ruled out and the source of the pain is unknown. The standard of care for most patients presenting with dyspeptic symptoms has been with proton pump inhibitors (PPI), regardless of whether or not the patient's symptoms include acid-related conditions, e.g., heartburn, GERD, etc. Although PPI treatment has yielded some success in these patients, there is a significant population of patients whose dyspeptic symptoms are not adequately treated with PPI's alone. The purpose of this study is to evaluate the use of dexloxiglumide in the treatment of the symptoms of functional dyspepsia in patients whose dyspeptic symptoms are not being treated adequately with PPI's.

NCT ID: NCT00298194 Completed - Dyspepsia Clinical Trials

The Effects of Z-338 in Subjects With and Without Functional Dyspepsia

Start date: February 2006
Phase: Phase 2
Study type: Interventional

To assess in subjects with and without functional dyspepsia the effects of Z-338 on: 1. Type and severity of symptoms a standardized nutrient challenge 2. The gastric nutrient distribution and gastric emptying of a standardized nutrient challenge 3. The association of the above with the manifestations of symptoms and symptom pattern

NCT ID: NCT00296582 Completed - Dyspepsia Clinical Trials

Gastric Motor Function Measurement in Dyspepsia and Normal Subjects

Start date: January 2006
Phase: N/A
Study type: Interventional

This study is being done to measure the functions of the stomach after eating a meal and to develop a new method that will simultaneously measure both gastric emptying and the relaxation of the stomach after a meal using nuclear medicine testing. This would make the testing more convenient for patients and will also offer better understanding of these two gastric functions.

NCT ID: NCT00285688 Completed - Dyspepsia Clinical Trials

Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital

Start date: June 2006
Phase:
Study type: Observational

Peptic ulcer disease is the most common gastrointestinal disease. Antibiotic resistant Helicobacter pylori is a major problem worldwide. The gold standard for Helicobacter pylori eradication is composed of Proton-pump inhibitor/Ranitidine bismuth citrate + Amoxycillin + Metronidazole /Clarithromycin. In Thailand, clarithromycin resistant strains increased and led to treatment failure. Data on file at Rajavithi Hospital showed that metronidazole resistant H. pylori was about 50% and Clarithromycin resistant strains accounted for 8%. This molecular genetic study will be performed in patients presenting with dyspepsia, who had an indication for gastroscopic examination, to explore the incidence of antibiotic resistant Helicobacter pylori in Rajavithi Hospital, Thailand.

NCT ID: NCT00277550 Withdrawn - Clinical trials for Constipation and Dyspepsia

The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

Start date: n/a
Phase: Phase 4
Study type: Interventional

To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia

NCT ID: NCT00275886 Recruiting - Dyspepsia Clinical Trials

Activation and Recruitment of GIL During Hp Infection

Start date: January 2006
Phase: N/A
Study type: Observational

Helicobacter pylori is a major human pathogen that infects over half of the world population. Infection initiates a series of changes in the gastric mucosa, beginning with gastritis and leading in some patients to peptic ulcer disease, mucosa-associated lymphomas, and gastric adenocarcinoma. It is believed that host factors, in particular, the T cell-mediated immune responses may play an important role in the pathogenesis of diseases induced by H. pylori infection. Recent results revealed that there were higher IFN-γ secreting cells in gastric infiltrating T cells isolated from H. pylori infected patients than in uninfected patients, suggesting that the TH1 response and degree of IFN-γ production is associated with disease severity. Meanwhile, recent studies have shown that apoptosis of the gastric epithelium is increased during infection and this response is associated with an expansion of gastric T-helper type 1 (Th1) cells. In this project, we are trying to further investigate role of host T cell mediated immune response in pathogenesis of Helicobacter infection by characterization of the expression of chemokine receptors on gastric infiltrating lymphocytes. We are going to investigate the mechanisms involving in chemokine/chemokine receptor interaction in recruitment of gastric infiltrating lymphocytes and pathogenesis of gastric mucosa damage in Helicobacter infection. This study will be helpful for understanding the mechanisms of activation and recruitment of gastric-infiltrating lymphocytes during gastric inflammation.

NCT ID: NCT00275795 Completed - Headache Clinical Trials

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

Start date: July 2005
Phase: Phase 1/Phase 2
Study type: Observational

Food allergy reactions cause various health disorders in sensitive people. These reactions may be IgE-mediated,cell-mediated, energy disturbance-mediated, or a combination of the three. Certain laboratory diagnostic procedures have been able to identify most IgE-mediated or cell-mediated food reactions, but so far there is no test available in traditional medicine to test the energy-mediated allergies and sensitivities. NAET® procedures have been able to identify food substances triggering to energ disturbances in sensitive people causing related health disorders. NAET uses one of the testing procedures called NST (Neuromuscular sensitivity testing).The efficacy of NST-NAET to screen food sensitivity will be evaluated in comparison with one of the well accepted, established, traditional medicine allergy testing known as the IgE-specific antigen test.